Boston Scientific Corporation: Beat — EPS $0.73, Revenue $5.14B
Earnings BeatQ3 2026 · Pre-market
Did Boston Scientific Corporation (BSX) beat earnings today?
Yes, Boston Scientific Corporation (BSX) beat Wall Street analyst expectations for Q3 2026, reporting higher-than-expected EPS and higher-than-expected revenue.
Earnings Per Share+1.39% surprise
$0.73Actual
Expected: $0.72
vs. year ago -2.7%
Total Revenue+1.74% surprise
$5.14BActual
Expected: $5.05B
vs. year ago +1.5%
Released Oct 28 · 6:30 AM ET
Earning Report
| Metric | Q3 2026 | Q3 2025 | YoY Change % |
|---|---|---|---|
| Revenue | $5.14B | $5.07B | +1.5% |
| Revenue detail — reported lines | |||
| └─Endoscopy | $741.00M | $747.00M | -0.8% |
| └─Urology | $661.00M | $682.00M | -3.2% |
| └─Neuromodulation | $331.00M | $293.00M | +13.1% |
| └─MedSurg | $1.73B | $1.72B | +0.6% |
| └─Cardiovascular | $3.41B | $3.34B | +1.9% |
| └─U.S. | $3.31B | $3.29B | +0.5% |
| └─EMEA | $829.00M | $793.00M | +4.4% |
| └─APAC | $797.00M | $802.00M | -0.6% |
| └─LACA | $203.00M | $175.00M | +16.0% |
| GAAP Basic EPS | $0.40 | $0.51 | -21.6% |
| GAAP Diluted EPS | $0.40 | $0.51 | -21.6% |
| Adjusted EPS | $0.73 | $0.75 | -2.7% |
| Net Income | $580.00M | $755.00M | -23.2% |
Financial Outlook / Guidance
| Metric | Q4 2026 Outlook | FY 2026 Outlook |
|---|---|---|
| Reported growth/(decline) | -3.0%--1.0% YoY | ~4.25% YoY |
| Foreign currency impact | —% | ~(0.5)% |
| Operational growth/(decline) | -3.0%--1.0% YoY | ~3.75% YoY |
| Acquisitions/divestitures impact | —% | —% |
| Organic growth/(decline) | -3.0%--1.0% YoY | ~3.75% YoY |
| Adjusted EPS | $0.77-$0.79 | $3.16-$3.18 |
Business Highlights
- ➤Commenced Elite AF trial enrollment for next-generation WATCHMAN Elite device.
- ➤Received FDA 510(k) clearance for Navigator Flex ureteral access sheath.
- ➤Received FDA 510(k) clearance for LithoVue Elite digital flexible ureteroscope.
- ➤Received FDA clearance for expanded SEISMIQ peripheral catheter sizes.
- ➤AMA assigned Category I CPT codes for renal denervation and ITNS devices effective January 2028.
- ➤Entered strategic collaboration with Heartflow for AI-powered CT-guided PCI planning.
- ➤Collaboration explores integration of Heartflow PCI Navigator with AVVIGO+ guidance system.
- ➤Global teams worked to restore operations following the cybersecurity incident.
Management Commentary
Mike Mahoney, Chairman and Chief Executive Officer, Boston Scientific
“This has been a challenging year for Boston Scientific and I'm proud of how our global teams have responded, particularly to the cybersecurity incident, working with urgency and resilience to restore operations and continue supporting customers and patients.”
Mike Mahoney, Chairman and Chief Executive Officer, Boston Scientific
“As we move forward, I remain confident in our long-term strategy, fueled by our dedicated talent, differentiated portfolio and strong pipeline of meaningful innovation.”